STAT+: Recursion, the AI drug development company, cuts more jobs after finalizing Exscientia merger

Recursion Pharmaceuticals, one of the most advanced companies using artificial intelligence and machine learning tools to expedite drug development, laid off employees after closing a merger last week.

Continue to STAT+ to read the full story…

Vistagen secures new patents for PH80 migraine treatment

Vistagen is developing PH80 as a hormone-free option for managing women’s health issues. Credit: sbw18/Shutterstock. Vistagen has expanded its global intellectual property (IP) portfolio with

July 10, 2024

Novel Vaccines Promising for Chikungunya, Cytomegalovirus

BOSTON — Vaccine candidates for chikungunya virus and for the ubiquitous cytomegalovirus performed well in human clinical trials, researchers reported here at the annual IDWeek

October 17, 2023

Optibrium acquires BioPharmics LLC, expanding its 3D drug design and visualisation offering

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the acquisition of BioPharmics LLC.

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.